Publication | Open Access
Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults
39
Citations
31
References
2019
Year
The cost-utility analysis suggested that RZV would be cost effective in the Canadian population compared with no vaccination and vaccination with ZVL at a willingness-to-pay threshold of $50,000.
| Year | Citations | |
|---|---|---|
Page 1
Page 1